Management of psoriatic arthritis: The therapeutic interface between rheumatology and dermatology

被引：28

作者：

Mease P. ^{[1
]}

机构：

[1] Division of Rheumatology Research, Swedish Medical Center, University of Washington School of Medicine, Seattle, WA 98104

来源：

Current Rheumatology Reports | 2006年 / 8卷 / 5期

关键词：

Psoriasis; Ankylose Spondylitis; Etanercept; Adalimumab; Psoriatic Arthritis;

D O I：

10.1007/s11926-006-0064-9

中图分类号：

学科分类号：

摘要：

Psoriatic arthritis is an inflammatory arthritis, which occurs in up to 30% of individuals with psoriasis. Dermatologists and other physicians treating psoriasis are in an ideal position to screen for the condition, and with rheumatologists, strategize optimal therapy. Mild skin and joint manifestations may be treated effectively with topical agents, ultraviolet light therapy, and nonsteroidal anti-inflammatory drugs. More severe manifestations of the disease, including progressive peripheral joint damage, spine disease, enthesitis, dactylitis, and severe skin changes, require systemic therapy. Traditional systemic agents include methotrexate, sulfasalazine, and cyclosporine. When these agents are not adequate or not tolerated, new biologic agents, particularly antitumor necrosis factor (TNF) compounds, have shown significant and enduring benefit in all disease domains, improvement in quality of life and function, and inhibition of progressive joint damage. Copyright © 2006 by Current Science Inc.

引用

页码：348 / 354

页数：6

共 63 条

[11]

Offidani A., Cellini A., Valeri G., Giovagnoni A., Subclinical joint involvement in psoriasis: Magnetic resonance imaging and X-ray findings, Acta Derm Venereol, 78, pp. 463-465, (1998)

[12]

Baeten D., Kruithof E., De Rycke L., Et al., Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy, Arthritis Res Ther, 7, (2005)

[13]

De Rycke L., Vandooren B., Kruithof E., Et al., Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy, Arthritis Rheum, 52, pp. 2146-2158, (2005)

[14]

Veale D., Ritchlin C., Fitzgerald O., Immunopathology of psoriasis and psoriatic arthritis, Ann Rheum Dis, 65, SUPPL. 2, (2005)

[15]

Kruithof E., Baeten D., De Rycke L., Et al., Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis, Arthritis Res Ther, 7, (2005)

[16]

Krueger J., Bowcock A., Psoriasis pathophysiology: Current concepts of pathogenesis, Ann Rheum Dis, 64, SUPPL. 2, (2005)

[17]

Mease P., Goffe B.S., Diagnosis and treatment of psoriatic arthritis, J Am Acad Dermatol, 52, pp. 1-19, (2005)

[18]

Fransen J., Antoni C., Mease P., Et al., Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: Analysis of data from randomized, controlled trials of two TNF inhibitors, Ann Rheum Dis, (2006)

[19]

Husted J.A., Gladman D.D., Cook R.J., Farewell V.T., Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis, J Rheumatol, 25, pp. 2146-2155, (1998)

[20]

Husted J.A., Gladman D.D., Farewell V.T., Et al., Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis, J Rheumatol, 24, pp. 511-517, (1997)

← 1 2 3 4 5 6 7 →